Navigation Links
Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results
Date:6/12/2008

BETHESDA, Md., June 12 /Xinhua-PRNewswire/ -- Chindex International, Inc. (Nasdaq: CHDX), an independent American provider of international healthcare services and Western healthcare products in the People's Republic of China, today announced results for its fiscal year end and fourth quarter ended March 31, 2008.

For the 2008 fiscal year, the Company reported total revenue of $130.1 million, an increase of 23% over the prior year, and income from continuing operations increased 80% to $8.3 million from $4.6 million in the prior year. Net income increased 34% to $3.7 million, or earnings per share of $0.32 compared to net income of $2.7 million or earnings per share of $0.29 for the year ended March 31, 2007.

For the quarter ended March 31, 2008, revenue was $34.6 million, an increase of 40% over the prior year, and income from continuing operations decreased 55% to $426,000 from $939,000 in the prior year. The net loss for the quarter ended March 31, 2008 was $2.7 million or loss per share of $0.20 compared to net income of $665,000, or earnings per share of $0.06, for the quarter ended March 31, 2007. The quarterly results were negatively impacted by certain non-routine year-end adjustments as well as the interest charge related to the conversion of a JP Morgan convertible bond.

The Company's balance sheet as of March 31, 2008 shows cash, cash equivalents and restricted cash of $80.4 million, total assets of $136.0 million, a current ratio of 4.51:1 and stockholders' equity of $87.4 million.

Roberta Lipson, President and CEO of Chindex, commented on the results: "We continue to see great opportunity for our healthcare businesses in China -- the world's fastest growing market. Our revenue growth and profitable
'/>"/>

SOURCE Chindex International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Chindex International Announces Shelf Registration, Related Strategy and Guidance
2. Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Fourth Quarter and Year End Results on Thursday, June 12, 2008
3. Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Third Quarter Results on Friday, February 8, 2008
4. Chindex International, Inc. to Present at 2008 UBS Global Healthcare Services Conference
5. Chindexs United Family Hospitals and Clinics and NBC Enter into Healthcare Services Agreement
6. JPMorgans Principal Investment Management Group to Invest in Chindex International, Inc.
7. LifeStem International, Inc. Announces Increased Revenues, Decreased Operating Expenses
8. MINRAD International, Inc. to Discuss 2008 First Quarter Financial Results on Tuesday, May 13, 2008
9. MINRAD International, Inc. Announces $40.0 Million Private Placement
10. China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network
11. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Toronto, Canada (PRWEB) May 24, 2013 ... selective barriers, and uptake or efflux transporters at the ... may be related to unbound fractions in the tissue ... understanding of these disposition challenges is required to guide ... and to identify any species-dependent variables that may impact ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a publicly traded ... development, sales and marketing of premium branded highly ... it is awarding exclusive Vestiage territories in the ... Illuminating Facial Care. Qualified applicants can request an ... to info(at)vestiageinc(dot)com and putting RELUMA in the "Subject" ...
(Date:5/23/2013)... , May 24, 2013 Die ... – Bei der englischen Version ... , 91 % der Teilnehmer einer groß angelegten Asthmaumfrage ... % laut GINA [*] -Definition [1] als kontrolliert ... mit Asthma generell einer von vier Denkweisen zugeordnet werden ...
(Date:5/23/2013)... 23, 2013 Venaxis, Inc. (Nasdaq:   APPY), ... obtaining FDA clearance and commercializing its rapid, protein biomarker-based ... of an underwritten public offering of 10,000,000 shares of ... shares of its common stock at an exercise price ... price of $1.25 per share and related warrant.  Venaxis ...
Breaking Biology Technology:DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
... /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation (TSX: NVN) today ... initiated dosing of the second cohort of,patients ... examining the safety of its,lead candidate, HspE7, ... to,cervical cancer. HspE7 is an investigational therapeutic ...
... there has been growing interest in the question, if ... via manure application is of environmental relevance. In a ... journal CLEAN, Kreuzig and co-workers now focused on the ... to the so far available data set on fate ...
... Dec. 5 The American Society of,Hematology (ASH), ... more than 20,000 attendees at the 49th ASH ... World Congress Center in,Atlanta. The meeting will premiere ... "The ASH annual meeting is the premier forum ...
Cached Biology Technology:Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial 2Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial 3Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial 4Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial 5New insights into the fate of anti-parasitics in manure and manured soils 249th Annual Meeting of the American Society of Hematology Will Feature the Latest Research in Blood Diseases 249th Annual Meeting of the American Society of Hematology Will Feature the Latest Research in Blood Diseases 3
(Date:5/24/2013)... system to combat metastatic cancer , Cancer cells ... the immune system. Stimulation of the immune system can ... factors that cause the immune system to ignore cancer ... to suppress the immune system response. In this issue ... led by Ronald Levy at Stanford University found that ...
(Date:5/24/2013)... scientists from around the world today issued a stark ... of one or two generations, the majority of the ... the handicap of severe pressure on fresh water, an ... substitute. This handicap will be self-inflicted and is, we ... chronic underlying problems led by mismanagement and sent a ...
(Date:5/23/2013)... at Rollins School of Public Health at Emory ... of Technology, have received a $4 million grant ... at Emory University (Health and Exposome Research Center: ... exposome-based center grant awarded in the United States. ... the National Institute of Environmental Health Sciences (NIEHS) ...
Breaking Biology News(10 mins):JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3
... you,re a dieter. Chronic dieters tend to ... according to a new study in the Journal ... M. Nowlis, Naomi Mandel, and Andrea C. Morales (all ... food packages that are marketed to help people control ...
... deceivingeven in life,s tiniest critters. From first detection in ... its recent characterization by the U.S. Department of Energy Joint ... adhaerens, appears to harbor a far more complex suite of ... August 21 online edition of the journal Nature, ...
... Scientists at The University of Manchester have developed a ... technology that could lead to quick testing for serious ... of new drugs. Researchers working at the Manchester ... unveiled a new technique for producing functional ,protein chips, ...
Cached Biology News:M&Ms as diet food? 100-calorie pack misconceptions 2Genome of simplest animal reveals ancient lineage, confounding array of complex capabilities 2Genome of simplest animal reveals ancient lineage, confounding array of complex capabilities 3Chips are down as Manchester makes protein scanning breakthrough 2
... ZMD.368. Immunogen: Synthetic peptide derived ... human WNT2B/WNT13 protein. Specificity: Specific ... and rat WNT2B/WNT13 proteins. Recognizes both ... Reactivity: Mouse Human Rat (positive controls: ...
Immunogen: Heat inactivated bacterial cells of Salmonella enteriditis,paratyphi and typhimurium Storage: 4 C...
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
... I-96 Plate can be used either in ... large-scale (i.e., 96-well) purification of DNA and/or ... unique silica-based matrix make it perfect for ... RNA in = 10 l eluate per ...
Biology Products: